Showing results (71-80 of 94) with videos related to
Sort By:
Pageof 10
European Journal of Human Genetics : EJHG|April 2, 2026
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in ItalyRossana Roncato, Samantha Perfler, Martina Gambron, et al.Pharmacological Research|November 7, 2012
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapySabrina Angelini, Maria Abbondanza Pantaleo, Gloria Ravegnini, et al.Journal of Gastroenterology|May 9, 2023
New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigeneticsGiovanni Dothel, Maria Raffaella Barbaro, Aldo Di Vito, et al.Cancer Science|May 28, 2022
Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic optionsGloria Ravegnini, Bruno Fosso, Riccardo Ricci, et al.Plants (Basel, Switzerland)|May 11, 2024
<i>Arbutus unedo</i> L. Fractions Exhibit Chemotherapeutic Properties for the Treatment of Gastrointestinal Stromal TumorsAldo Di Vito, Manuela Mandrone, Ilaria Chiocchio, et al.The Pharmacogenomics Journal|September 22, 2018
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumorGloria Ravegnini, Milena Urbini, Vittorio Simeon, et al.Journal of Gynecologic Oncology|September 24, 2023
Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survivalCamelia Alexandra Coada, Giulia Dondi, Gloria Ravegnini, et al.Epigenomics|September 15, 2016
Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumorsMaria Abbondanza Pantaleo, Gloria Ravegnini, Annalisa Astolfi, et al.Cancers|March 6, 2021
<i>ARID1A</i> and <i>CTNNB1</i>/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular ClassificationAntonio De Leo, Dario de Biase, Jacopo Lenzi, et al.Clinical Epigenetics|January 9, 2019
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agentsRiccardo Ricci, Maurizio Martini, Gloria Ravegnini, et al.Pageof 10